Ohtuvayre denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for ohtuvayre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna's Step-Therapy Protocol Blocks Ohtuvayre

Ohtuvayre (ensifentrine) is a dual PDE3/PDE4 inhibitor inhaled COPD maintenance therapy occupying a newer mechanistic class. Aetna's step-therapy (also called "fail-first") protocol for COPD requires that patients demonstrate an adequate trial of one or more preferred, lower-cost agents — typically established bronchodilator classes — before the plan will authorize a newer brand agent. A step-therapy denial means the plan has no record that those prior steps were tried and documented, not necessarily that you haven't taken them.

## Why This Denial Is Appealable

Step-therapy denials are frequently overturned when a complete treatment history is submitted. Additionally, many states have enacted step-therapy override laws for fully insured plans, and ERISA plans must still provide a full-and-fair review:

• Internal appeal (ERISA §503 / ACA §2719): Submit your prior treatment history with the appeal. If you have already tried and failed the required step agents, that history satisfies the protocol.
• Step-therapy exception: Most plans have an explicit exception pathway when required steps have already been tried, are contraindicated, or would cause clinically significant harm. Request this exception simultaneously with your appeal.
• External review (ACA §2719): After internal exhaustion or at the 4-month mark, an Independent Review Organization reviews the clinical record. The window is typically 4 months from the denial notice.
• State step-therapy law: If your plan is a fully insured state-regulated plan (not self-funded ERISA), your state may have a step-therapy override law. Cite this in your appeal if applicable.
• Expedited review: Available if standard timelines would seriously jeopardize your health.

## Documentation to Gather

1. Step-therapy requirements: Obtain Aetna's published step-therapy protocol for Ohtuvayre (Clinical Policy Bulletin, aetna.com). List every required step agent explicitly. 2. Prior treatment history: For each required step agent you have tried, document: the drug name, start date, stop date, dose per the treating physician's notes, and the specific reason the agent was inadequate (lack of efficacy, adverse effect, contraindication). 3. Prescriber attestation: A letter from your physician confirming that the required step agents have been tried and failed, or that they are clinically contraindicated, and explaining why Ohtuvayre is now medically necessary. 4. Objective severity data: Spirometry, exacerbation logs, or emergency/urgent care visits while on prior step agents that demonstrate inadequate disease control. 5. Urgent-start documentation: If rapid initiation is needed for clinical reasons, document why delaying Ohtuvayre to retry step agents would cause harm.

## Criteria-Mapping Structure

Create a table with one row per required step-therapy agent. For each, record the drug name, the dates of your trial, the outcome, and the source document. This maps your history directly to the protocol requirements. Attach supporting chart notes as tabbed exhibits. Reviewers cannot grant an exception without evidence — a well-organized table makes denial much harder to sustain.

## Next Step

Ask your prescriber's office whether they can submit a peer-to-peer review request directly to Aetna's medical director. Peer-to-peer calls frequently resolve step-therapy denials faster than written appeals when the clinical picture is clear.